CAS: 150-59-4; Alverine

该化合物是一种化学化合物,主要用作抗呼吸道消毒剂,特别是用于治疗胃肠紊乱,被归类为光滑的肌肉放松剂,有助于缓解消化道中的抽搐.甲草胺通常以麻风沙质形式出现,这是一种盐状,可增加其溶解性和生物利用率.该化合物的分子重量相对较低,其特点是能够有选择地瞄准光滑的肌肉组织,从而有效地减少与肠胃综合症等条件有关的抽筋和不适.甲草素的功能包括抑制钙离子流入光滑的肌肉细胞,导致放松.它一般是良好的,尽管有些人可能受到诸如胃部或头晕眩等副作用.与任何药物一样,在医疗监督下使用甲草素对于确保安全和效率至关重要,特别是在有基本健康状况的病人或服用其他药物的人中.

结构式图片

上下游产品

CAS号74-96-4 溴乙烷 | CAS号93948-20-0 BIS-(3-PHENYL-P... | CAS号75-04-7 乙胺 | CAS号104-52-9 3-苯基-1-氯丙烷 | CAS号557-66-4 乙胺盐酸盐 | CAS号104-55-2 肉桂醛

合成工艺路线路线简述

    📜3-苯基-1-丙胺置于5 % Pd/tio2体系中,化学反应 25.0H,反应生成阿尔维林
    参考文献:Pd / Tio 2-常温下伯胺向光催化仲胺的光催化自缩合
    标题:Pd / Tio 2-常温下伯胺向光催化仲胺的光催化自缩合
    摘要:对称的仲胺是通过伯胺在负载钯的二氧化钛(pd / Tio 2)光催化剂上的自缩合反应合成的.反应在环境温度(30°C,在环戊基甲基醚中)下以中等至优异的分离产率提供了一系列仲胺.一锅药物合成的适用性通过胺的自缩合,然后用醇对所得仲胺进行n-烷基化的光催化反应顺序来证明.
    Doi:10.1021/acs.Orglett.8B03271

    海关参考信息

    专利信息


    专利号:US-7662401-B2
    优先权日:2002-04-08
    标 题 :Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase
    发明人:MAHE YANN; MEYBECK ALAIN
    权利人:OREAL
    摘要:The present invention relates to the cosmetic or pharmaceutical use of an extract of a nonfruiting nonphotosynthetic filamentous bacterium in a composition containing a cosmetically or pharmaceutically acceptable medium, as an agent increasing the endogenous synthesis of superoxide dismutase, in particular for preventing and/or limiting the formation of free radicals and/or removing the free radicals present in cells; in addition, the invention relates to a composition comprising at least one extract of Vitreoscilla filiformis and lycopene.

    专利号:US-2003224077-A1
    优先权日:2002-04-08
    标 题:Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase

    专利号:US-7662997-B2
    优先权日:2004-12-30
    标 题 :Synthesis and applications of 2-oxo-4-methylthiobutyric acid, its salts and its derivatives
    发明人:REY PATRICK; BLANCHARD GILBERT
    权利人:ADISSEO IRELAND LTD
    摘要:The invention relates to a process for preparing 2-oxo-4-methylthiobutyric acid (I), its salts and its derivatives n n n n n n n n n n n n in which R represents a group chosen from COOH, COOR′, NH 2 , NHR′ or NR′R″, where R′ and R″ are chosen, independently of one another, from the group of linear or branched alkyl radicals having from 1 to 12 carbon atoms and cycloalkyl radicals having from 3 to 12 carbon atoms, n according to which process but-3-ene-1,2-diol (II) is catalytically and selectively oxidized to give 2-oxobut-3-enoic acid (III) and methyl mercaptan is selectively condensed with 2-oxobut-3-enoic acid (III). n 2-Oxo-4-methylthiobutyric acid (I), its salts and its derivatives are used as food supplement, in particular in animal nutrition.

    专利号:US-2007237746-A1
    优先权日:2002-04-08
    标题:Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase

    专利号:US-2010291007-A1
    优先权日:2002-04-08
    标题 :Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase

    专利号:EP-2153815-A1
    优先权日:2008-08-05
    标题 :Use of urea containing compositions
    发明人:TRULLAS CABANAS CARLOS RAMON; KRUTMANN JEAN PROF DR
    权利人:ISDIN SA
    摘要:The present invention relates to the use of a composition comprising urea for increasing the expression of at least one gene associated with the collagen synthesis within the dermis of the skin. nThe urea composition has been used for preventing/treating damages of the skin such as signs of aging, wrinkles, damages associated with UV-radiation, wounds, skin diseases.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro-Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014 Feb;68(2):245-54. doi: 10.1111/ijcp.12333. Epub 2013 Oct 21.
    2: Lee SH, Athavankar S, Cohen T, Piran R, Kiselyuk A, Levine F. Identification of alverine and benfluorex as HNF4α activators. ACS Chem Biol. 2013 Aug 16;8(8):1730-6. doi: 10.1021/cb4000986. Epub 2013 May 29.
    3: Bueno L, Beaufrand C, Theodorou V, Andro-Delestrain MC. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association. J Pharm Pharmacol. 2013 Apr;65(4):567-73. doi: 10.1111/jphp.12021. Epub 2013 Jan 17. doi: 10.1016/j.ejphar.2014.08.033. Epub 2014 Sep 6. doi: 10.1002/dta.130. doi: 10.1111/j.1365-2036.2009.04216.x. Epub 2009 Dec 10. doi: 10.3748/wjg.v20.i20.6031. Review.

    合成参考文献


    摘要:Journal of Hepathology., 27(399), 1997 []
    摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
    摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知